Go on. Now lets add everything from patents and direct. All of the improvements. Proper maturation and cytokine expression improving the potency. I hipe they follow up tuesday with a "but wait there is more". I know its crazy but what if they slightly tweaked the maturation process in L after learning from the direct trial about method B. Our German poster noted the latter half are doing better. It could be from the imbalance of placebo or potentially a tweak in the purity if dose. Another tiral within a trial like direct. Conspicuous timing with the halt. Im just spitballin but if L is as good as it is now without tweaks imagine L 2.0 And direct 2.0. Then take the pdl1 breaks off if needed and supress any other tumur recruited freindlies. They know the make up if the long term survivors. Now the question will be how to we make the other patients more like the long term survivors. How about a using drugs to convert or push patients to a mesenchymal signature? Which we should also point out again LL has said several times all patients do better but the better performers generally come from the pool of patients with a more mesenchymal signature, which are traditionaly patients with a shorter mos. If that doesnt shift a curve to the right I dont know what does. Everyone opining about external controls must have forgot about all of the drugs approved from open label phase 2 and 3 trials. The risk reward for a patient is in our favor. And now we know from after market close on friday, the trial data WILL be presented on Tuesday. I think the delays have created a suoer volcano instead if just a normal eruption, the pressure has been building for much longer and we may see a black(white) swan event and an eruption felt around the world.
News 
Market Data 
Discover 
